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Objective. To examine the efficacy of methotrexate monotherapy relative to etanercept monotherapy and the 
value of combining methotrexate and etanercept for the treatment of patients with psoriatic arthritis (PsA).
Methods. In this double- blind study, 851 patients with PsA were randomized to 1 of 3 treatment arms, as follows: 
oral methotrexate (20 mg) plus subcutaneous placebo given weekly (n = 284), subcutaneous etanercept (50 mg) 
plus oral placebo given weekly (n = 284), or subcutaneous etanercept (50 mg) plus oral methotrexate (20 mg) given 
weekly (combination therapy; n = 283). The American College of Rheumatology 20% improvement (ACR20) response 
and Minimal Disease Activity (MDA) response at week 24 were the primary end point and key secondary end point, 
respectively. Other measures of inflammatory arthritis, radiographic progression, and nonarticular disease manifes-
tations were also assessed.
Results. Patients with PsA had a mean ± SD age of 48.4 ± 13.1 years, and the mean ± SD duration of PsA was 3.2 
± 6.3 years (median 0.6 years). ACR20 and MDA response rates at week 24 were significantly greater in patients who 
received etanercept monotherapy compared with those who received methotrexate monotherapy (ACR20, 60.9% 
versus 50.7% of patients [P = 0.029]; MDA, 35.9% versus 22.9% of patients [P = 0.005]), and both were significantly 
greater in the combination therapy group compared with the methotrexate monotherapy group at week 24 (ACR20, 
65.0% versus 50.7% of patients [P = 0.005]; MDA, 35.7% versus 22.9% of patients [P = 0.005]). Other secondary 
outcomes (ACR50 and ACR70 response rates, proportions of patients achieving a Very Low Disease Activity score, 
and PsA disease activity scores) showed between- group differences that were consistent with the primary and key 
secondary end point results. Furthermore, patients in both etanercept treatment arms showed less radiographic pro-
gression at week 48 compared with patients who received methotrexate monotherapy. Outcomes were similar in the 
combination therapy and etanercept monotherapy groups, except for some skin end points. No new safety signals 
were seen.
Conclusion. Etanercept monotherapy and combination therapy with etanercept and methotrexate showed 
 greater efficacy than methotrexate monotherapy in patients with PsA, according to the ACR and MDA response rates 
and extent of radiographic progression at follow- up. Overall, combining methotrexate and etanercept did not improve 
the efficacy of etanercept.
ClinicalTrials.gov identifier: NCT02376790.
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INTRODUCTION
Psoriatic arthritis (PsA) is a chronic, systemic inflammatory 
arthritis of the peripheral joints and axial skeleton that is com-
monly associated with psoriasis (1). Clinical manifestations include 
dactylitis, enthesitis, and nail changes, as well as joint erosions 
frequently seen on radiographs (1). PsA occurs in up to 30% of 
patients with psoriasis (2). The annual incidence of PsA in patients 
with psoriasis has been reported to be 1–3% (3–5).
Early treatment of PsA may help prevent the impaired func-
tion and deformities caused by joint destruction (6–8). Agents 
used to treat PsA include disease- modifying antirheumatic drugs 
(DMARDs) such as methotrexate and tumor necrosis factor 
(TNF) inhibitors (9,10). Additional agents that have recently been 
approved for use in PsA include biologic inhibitors of the interleu-
kin- 12 (IL- 12)/IL- 23 and IL- 17 pathways (11–13) and small mole-
cule inhibitors of janus kinase (14) and phosphodiesterase 4 (15). 
Although methotrexate is widely used to treat PsA and is approved 
by the US Food and Drug Administration (FDA) for use in psoriasis, 
it is not approved by the FDA for the treatment of PsA. Therefore, 
there is a need to better understand its efficacy in PsA (16–18).
Prior trials comparing methotrexate with a biologic agent 
included patients who were inadequate responders to methotrex-
ate (19), thus limiting the ability to clearly understand the efficacy of 
methotrexate in comparison with an established biologic therapy 
in methotrexate- naive patients. In the Remicade Study in Psori-
atic Arthritis Patients of Methotrexate-Naive Disease (RESPOND) 
trial (20), investigators studied the efficacy of methotrexate in 
methotrexate- naive patients, but it was an open- label study that 
compared methotrexate with infliximab in combination with meth-
otrexate, obscuring the ability to directly compare the efficacy of 
methotrexate and infliximab as monotherapies. The Methotrexate 
in Psoriatic Arthritis (MIPA) study, a randomized clinical trial com-
paring methotrexate with placebo in methotrexate- naive patients, 
failed to demonstrate statistically significant differences between 
the 2 study arms at 24 weeks (21). However, the overall findings 
were inconclusive, possibly because of a high dropout rate and use 
of a submaximal methotrexate target dosage of 15 mg/week (21).
The efficacy of TNF inhibitors has been demonstrated in 
PsA (22–27), but the benefit of combining methotrexate and TNF 
inhibitors remains unclear. In rheumatoid arthritis, the Trial of Etan-
ercept and Methotrexate with Radiographic Patient Outcomes 
(TEMPO) study (28) (and analogous trials with other TNF inhib-
itors) have established that methotrexate used in combination 
with a TNF inhibitor increases the efficacy of the TNF inhibitor. 
No  comparable study has been conducted in PsA, and results of 
observational studies have suggested that, unlike in rheumatoid 
arthritis, no additional efficacy is added by combining methotrex-
ate with a TNF inhibitor in PsA (29,30).
We therefore undertook the current randomized, controlled 
trial to examine the comparative efficacy of methotrexate mono-
therapy relative to TNF inhibitor monotherapy in methotrexate- 
naive patients with PsA early in the course of their disease. This 
trial also assessed the effect of combining methotrexate with a 
TNF inhibitor for the treatment of PsA in this patient population.
PATIENTS AND METHODS
Study design and population. The Study of Etanercept 
and Methotrexate in Subjects with Psoriatic Arthritis (SEAM- PsA) 
trial was a 48- week phase III, multicenter, randomized, double- 
blind international study (31). Following the 48- week double- 
blind period, there was a 30- day safety follow- up period. Study 
patients were adults age ≥18 years with active PsA (based on the 
Classification Criteria for Psoriatic Arthritis [32]) who were naive 
to treatment with etanercept and other biologic agents, and had 
no prior use of methotrexate for PsA. Prior treatment with metho-
trexate was allowed for psoriasis if discontinuation had not been 
due to toxicity or intolerance, and if the methotrexate had been 
discontinued ≥6 months prior to initiation of the investigational 
product. Patients had to have 3 tender joints and 3 swollen joints 
(based on 68- and 66- joint counts, respectively) at screening and 
at baseline, and an active psoriatic skin lesion that was ≥2 cm in 
diameter. For patients who were receiving nonsteroidal antiinflam-
matory drugs (NSAIDs), the dose had to be stable ≥2 weeks prior 
to initiation of the investigational product. For patients receiving 
oral corticosteroids, the dose had to be stable (not to exceed the 
equivalent of 10 mg prednisone per day) ≥4 weeks prior to ini-
tiation of the investigational product (for a complete description 
of the patient inclusion and exclusion criteria, see Supplementary 
Methods, available on the Arthritis & Rheumatology web site at 
http://onlinelibrary.wiley.com/doi/10.1002/art.40851/abstract).
Patients were enrolled in the study at 124 hospital centers 
or clinics in 17 countries (for a list of the investigators and 
countries in which the study was conducted, see Supplemen-
tary Methods at http://onlinelibrary.wiley.com/doi/10.1002/
art.40851/abstract). Patients were randomized 1:1:1 to 1 of 
3 treatment arms, as follows: oral methotrexate (target dose 
20 mg) plus subcutaneous placebo given weekly, subcutane-
ous etanercept (target dose 50 mg) plus oral placebo given 
and efficacy issues already addressed in the product labeling. A committee 
of internal advisors will review requests. If not approved, requests may be 
further arbitrated by a Data Sharing Independent Review Panel. Requests 
that pose a potential conflict of interest or an actual or potential competitive 
risk may be declined at Amgen’s sole discretion and without further 
arbitration. Upon approval, information necessary to address the research 
question will be provided under the terms of a data sharing agreement. This 
may include anonymized individual patient data and/or available supporting 
documents, containing fragments of analysis code where provided in 
analysis specifications. Further details are available at https://wwwext.
amgen.com/science/clinical-trials/clinical-data-transparency-practices/.
Address correspondence to Philip J. Mease, MD, Seattle Rheumatology 
Associates, 601 Broadway Suite 600, Seattle, WA 98122. E-mail: pmease@
philipmease.com.
Submitted for publication November 9, 2018; accepted in revised form 
February 5, 2019.
MEASE ET AL 1114       |
weekly, or subcutaneous etanercept (target dose 50 mg) plus 
oral methotrexate (target dose 20 mg) given weekly. At or after 
week 24, patients with an inadequate response to treatment 
(i.e., showing <20% improvement from baseline in tender joint 
counts and <20% improvement from baseline in swollen joint 
counts) received rescue therapy with etanercept plus metho-
trexate until week 48. Patients who were withdrawn or removed 
were not replaced. Patients were randomized via an interac-
tive voice- response system, based on a computer- generated 
randomization schedule that was prepared by the study spon-
sor before the start of the trial. Each patient was assigned a 
single, unique randomization number. Treatment assignments 
were maintained within the interactive voice- response system.
Both patients and investigators were blinded with regard 
to the randomized treatment assignments. Original treatment 
assignments remained blinded until patients reached week 48 or 
had an early termination visit (whichever occurred first). Treatment 
assignment was only unblinded when knowledge of treatment 
was essential to further patient care. Blinding was achieved by 
using matching prefilled syringes for the etanercept and injectable 
placebo administrations, and by using matching capsules for the 
methotrexate and oral placebo administrations.
Etanercept is a dimeric fusion protein (comprising the extra-
cellular ligand- binding domain of the human TNF p75 receptor 
linked to the Fc portion of human IgG1) that inhibits the activity 
of TNFα and TNFβ (33). For the SEAM- PsA trial, etanercept was 
manufactured and provided by Immunex (a subsidiary of Amgen 
Inc.) in single- use, prefilled 1- ml syringes. Etanercept was admin-
istered at a dosage of 50 mg/week by subcutaneous injection, as 
recommended in the US prescribing information for use of etaner-
cept in PsA (33).
The first dose of etanercept was administered at the study 
site, and subsequent injections were administered by the patient or 
a caregiver. Methotrexate, supplied as 2.5- mg tablets in capsules 
(for blinding purposes), was initiated at a dosage of 10 mg/week 
and titrated up to 20 mg/week over a 4- week period. If patients 
developed a toxic reaction to methotrexate, the methotrexate 
dosage could be reduced to as low as 10 mg/week. Folic acid 
was administered at 5–7 mg/week. Patients entering the study 
taking oral corticosteroids had to remain on a stable dose up to 
week 24. Those taking acetaminophen, narcotic analgesics, or 
NSAIDs had to remain on a stable dose up to week 24 and could 
not take these agents within 12 hours (24 hours for oxycontin) 
before a scheduled study visit.
Registration and ethics review. The SEAM- PsA study 
has been completed, and is registered at https://ClinicalTrials.gov . 
The study was conducted in accordance with the Declaration of 
Helsinki. All patients provided written informed consent, and each 
participating site obtained protocol approval by an institutional 
review board. A data monitoring committee did not oversee this 
study.
Study outcome measures. Outcomes were measured 
at baseline and at weeks 4, 8, 12, 16, 24, 36, and 48. The pri-
mary end point was achievement of ≥20% improvement in the 
American College of Rheumatology response (ACR20) criteria (34) 
at week 24. (For detailed descriptions and scales for all of the 
outcome measures used, see Supplementary Table 1, available 
on the Arthritis & Rheumatology web site at http://onlinelibrary.
wiley.com/doi/10.1002/art.40851/abstract.) The key secondary 
end point was the Minimal Disease Activity (MDA) response (35) 
Figure 1. Diagram of patient allocation.
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Table 1. Baseline demographic and disease characteristics of the patients in each treatment group*
Methotrexate  
monotherapy 
(n = 284)
Etanercept  
monotherapy 
(n = 284)
Combination  
therapy 
(n = 283)
Age, mean ± SD years 48.7 ± 13.1 48.5 ± 13.5 48.1 ± 12.7
Sex, no. (%) female 160 (56.3) 133 (46.8) 139 (49.1)
Race, no. (%) white 255 (89.8) 252 (88.7) 265 (93.6)
Duration of PsA, mean ± SD years (no. assessed) 3.6 ± 6.8 (231) 3.1 ± 6.0 (222) 3.0 ± 6.0 (231)
Prior use of nonbiologic DMARD, no. (%) 38 (13.4) 26 (9.2) 43 (15.2)
Body mass index, mean ± SD kg/m2 (no. assessed) 30.6 ± 7.1 (284) 30.4 ± 6.6 (283) 30.0 ± 6.7 (283)
≤30 kg/m2, no. (%) 146 (51.4) 153 (53.9) 160 (56.5)
>30 kg/m2, no. (%) 138 (48.6) 130 (45.8) 123 (43.5)
Swollen joint count (of 66 joints), mean ± SD  
(no. assessed)
12.9 ± 9.9 (284) 11.5 ± 9.6 (283) 11.2 ± 9.1 (282)
Tender joint count (of 68 joints), mean ± SD  
(no. assessed)
20.9 ± 15.0 (284) 18.8 ± 14.5 (283) 20.0 ± 15.3 (282)
PASDAS, mean ± SEM (no. assessed) 6.09 ± 0.07 (282) 6.05 ± 0.07 (279) 6.04 ± 0.07 (280)
DAPSA, mean ± SEM (no. assessed) 46.5 ± 1.4 (283) 43.4 ± 1.4 (281) 43.8 ± 1.4 (281)
LDI
Patients with score >0 at baseline, no. (%) 98 (34.5) 96 (33.8) 90 (31.8)
Mean ± SEM score (no. assessed) 164.9 ± 26.9 (98) 147.6 ± 20.8 (96) 138.2 ± 23.9 (90)
SPARCC Enthesitis Index
Patients with score >0 at baseline, no. (%) 191 (67.3) 189 (66.5) 196 (69.3)
Mean ± SEM score (no. assessed) 5.7 ± 0.3 (191) 5.5 ± 0.3 (189) 5.9 ± 0.3 (196)
Psoriasis- affected BSA, mean ± SD % 12.7 ± 18.8 10.8 ± 14.7 10.7 ± 15.6
Patients with ≥3% affected BSA at baseline, no. (%) 192 (67.6) 179 (63.0) 177 (62.5)
Mean ± SEM % affected BSA 18.1 ± 1.5 16.4 ± 1.2 16.4 ± 1.3
Patients with ≥10% affected BSA at baseline, no. (%) 99 (34.9) 97 (34.2) 90 (31.8)
Mean ± SEM % affected BSA 30.3 ± 2.3 25.9 ± 1.7 27.3 ± 2.0
sPGA
All patients, mean ± SD score 2.6 ± 1.1 2.6 ± 1.0 2.5 ± 1.0
Patients with ≥3% affected BSA at baseline, mean ± 
SEM score (no. assessed)
2.9 ± 0.1 (191) 2.9 ± 0.1 (179) 2.9 ± 0.1 (177)
Patients with ≥10% affected BSA at baseline, mean ± 
SEM score (no. assessed)
3.2 ± 0.1 (99) 3.1 ± 0.1 (97) 3.3 ± 0.1 (90)
mNAPSI
Patients with score >0 at baseline, no. (%) 185 (65.1) 206 (72.5) 197 (69.6)
Mean ± SEM score (no. assessed) 3.4 ± 0.2 (183) 3.5 ± 0.2 (205) 3.6 ± 0.2 (195)
HAQ DI, mean ± SEM score (no. assessed) 1.27 ± 0.04 (283) 1.15 ± 0.04 (284) 1.15 ± 0.04 (282)
SF- 36, mean ± SEM score (no. assessed)
Overall 80.8 ± 0.9 (282) 82.9 ± 0.9 (284) 83.6 ± 0.9 (282)
MCS 45.2 ± 0.7 (282) 45.1 ± 0.7 (284) 46.3 ± 0.7 (282)
PCS 35.6 ± 0.5 (282) 37.8 ± 0.5 (284) 37.4 ± 0.6 (282)
SHS
Total, mean ± SEM score (no. assessed) 2.76 ± 0.12 (269) 2.97 ± 0.13 (273) 2.70 ± 0.12 (274)
Erosion score >0, no./total no. (%) 223/269 (82.9) 220/273 (80.6) 224/274 (81.8)
* PsA = psoriatic arthritis; DMARD = disease- modifying antirheumatic drug; PASDAS = Psoriatic Arthritis Disease Activity Score; DAPSA = 
Disease Activity Index for Psoriatic Arthritis; LDI = Leeds Dactylitis Index; SPARCC = Spondyloarthritis Research Consortium of Canada; BSA = 
body surface area; sPGA = static Physician’s Global Assessment (of psoriasis); mNAPSI = modified Nail Psoriasis Severity Index; HAQ DI = 
Health Assessment Questionnaire disability index; SF- 36 = Short- Form 36 Health Survey; MCS = mental component summary; PCS = physical 
component summary; SHS = van der Heijde modification of the total Sharp score (of radiographic progression). 
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at week 24. Secondary end points included the ACR20 and MDA 
response rates analyzed at other time points, as well as ACR50 
and ACR70 response rates analyzed at all time points.
Additional end points, assessed at weeks 24 and 48, included 
the following: Very Low Disease Activity (VLDA) response (35), 
Psoriatic Arthritis Disease Activity Score (PASDAS) (36), Disease 
Activity Index for Psoriatic Arthritis (DAPSA) score (37), change 
from baseline in both the Leeds Dactylitis Index (LDI) (38) and the 
Spondyloarthritis Research Consortium of Canada (SPARCC) 
Enthesitis Index (39), dermatologic end points of the percentage 
of psoriasis- affected body surface area (BSA) (40), the static Phy-
sician’s Global Assessment (sPGA) of psoriasis (41), and modified 
Nail Psoriasis Severity Index (mNAPSI) (42), and patient- reported 
outcomes from the Health Assessment Questionnaire disability 
index (HAQ DI) (43) and the 36- item Short Form (SF- 36) Health 
Survey (44).
Radiographic end points included change from baseline in 
radiographic progression scores using the van der Heijde modifi-
cation of the total Sharp score (SHS) (45), and rates of radiographic 
nonprogression at weeks 24 and 48. Radiographs of the hands 
and feet were obtained from patients locally and read centrally 
by 2 independent readers to assess erosions and joint space 
 narrowing.
Safety analyses examined the incidence of adverse events, 
serious adverse events, and adverse events leading to discontin-
uation of the investigational product at weeks 24 and 48.
Statistical analysis. For the SEAM- PsA study, we esti-
mated that a sample size of 840 patients would provide a 
marginal power of >90% to detect treatment differences in the 
ACR20 response at week 24 between the etanercept-containing 
arms and the methotrexate monotherapy arm, at a 2- sided sig-
nificance level of 0.025. This estimate assumed a randomization 
ratio of 1:1:1 to the 3 study arms (adjusting for an anticipated 
10% dropout rate) and assumed an ACR20 response rate of 65% 
for the etanercept plus methotrexate combination arm, 60% for 
the etanercept monotherapy arm, and 44% for the methotrex-
ate monotherapy arm. A sample size of 840 patients was also 
estimated to provide a marginal power of >90% to detect treat-
ment differences in the MDA response at week 24 between the 
etanercept- containing arms and the methotrexate monotherapy 
arm, at a 2- sided significance level of 0.025, assuming response 
rates of 35% for the etanercept plus methotrexate combination 
therapy arm, 30% for the etanercept monotherapy arm, and 
15% for the methotrexate monotherapy arm. These assumed 
response rates for the ACR20 and MDA responses were esti-
mates based on data from previous studies (21,22,29,35,46) and 
on the assumption that generally higher responses than those 
reported in the literature would occur in the SEAM- PsA trial since 
it enrolled patients whose disease course was anticipated to be 
in a relatively early phase and who were naive to treatment with 
biologics and methotrexate for PsA.
Analyses were conducted using SAS version 9.4 (SAS 
Institute). The main analyses of the primary and key secondary 
end points were based on the full analysis set, which included 
all randomized patients analyzed according to randomization 
assignment (intent- to- treat analysis). Missing data were imputed 
as nonresponder data. The treatment differences between etan-
ercept plus methotrexate combination therapy and methotrexate 
monotherapy, and between etanercept monotherapy and metho-
trexate monotherapy were tested in a Bonferroni- based gatekeep-
ing chain procedure (47) to control the family- wise, 2- sided Type 
I error rate at 0.05 (see Supplementary Figure 1, available on the 
Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/
doi/10.1002/art.40851/abstract). Between- treatment compari-
sons were adjusted using the Cochran- Mantel- Haenszel test, with 
baseline body mass index status (≤30 kg/m2 or >30 kg/m2) and 
prior treatment with a non–biologic DMARD being used as stratifi-
cation factors. The risk difference between groups was estimated 
using the Mantel- Haenszel estimate of common risk difference 
(using the same stratification factors mentioned above).
Efficacy end points other than the primary and key secondary 
end points were analyzed as observed and not adjusted for multi-
plicity; therefore, P values are unadjusted and considered descrip-
tive. Safety end points were summarized descriptively based on 
the safety analysis set, which included patients who received ≥1 
dose of active investigational product. Patients were analyzed 
according to actual treatment received.
RESULTS
Between March 3, 2015 and July 7, 2017, a total of 851 
patients (of 1,080 screened) were enrolled in the SEAM- PsA 
trial (229 patients did not meet the eligibility criteria) and ran-
domized to receive a treatment (Figure  1). The last patient 
completed the study on July 6, 2018. Of the 851 enrolled 
patients, 284 were randomized to receive methotrexate mon-
otherapy, 284 to receive etanercept monotherapy, and 283 to 
receive methotrexate plus etanercept (combination therapy) 
(Figure 1). Of the 851 patients, 44% were from North Amer-
ica, 27% from Europe, 16% from Latin America, 9% from 
Russia, and 4% from South Africa. The number of patients 
who received their intended treatment was 282 (99.3%) in the 
methotrexate monotherapy arm, 284 (100%) in the etanercept 
monotherapy arm, and 282 (99.6%) in the combination ther-
apy arm. A total of 691 patients (81.2%) completed the trial. 
The most common reason for study discontinuation was with-
drawal of consent. The primary end point was analyzed using 
the full analysis set of 851 randomized patients.
The 3 treatment arms were generally balanced with 
respect to baseline demographic and disease characteristics 
(Table 1). Most patients were white (90.7%), and the mean ± 
SD age was 48.4 ± 13.1 years. The duration of PsA was 
a mean ± SD 3.2 ± 6.3 years (median 0.6 years); overall, 
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56% of patients had a disease duration of ≤2 years. In total, 
12.6% of the patients had received prior treatment with a 
 nonbiologic DMARD (42 patients [5%] had received metho-
trexate prior to the study). Prior treatment with a nonbiologic 
DMARD occurred in 13.4%, 9.2%, and 15.2% of patients in 
the methotrexate monotherapy, etanercept monotherapy, and 
combination arms, respectively (Table  1). From weeks 4 to 
24, patients in both of the methotrexate- containing treatment 
arms achieved and maintained a mean methotrexate dose of 
>18.8 mg (median 20 mg) (average weekly doses are listed in 
Supplementary Table 2, available on the Arthritis & Rheuma-
tology web site at http://onlinelibrary.wiley.com/doi/10.1002/
art.40851/abstract). The percentage of patients who received 
rescue therapy at or after week 24 was 24.3% in the metho-
trexate monotherapy arm, 16.2% in the etanercept monother-
apy arm, and 12.7% in the combination therapy arm.
The proportion of patients achieving an ACR20 response 
at week 24 (primary end point) was significantly greater among 
those receiving etanercept monotherapy compared with those 
receiving methotrexate monotherapy (173 [60.9%] of 284 
patients versus 144 [50.7%] of 284 patients; adjusted P = 0.029) 
and significantly greater among those receiving combination 
therapy compared with those receiving methotrexate monother-
apy (184 [65.0%] of 283 patients versus 144 [50.7%] of 284 
patients; adjusted P = 0.005) (Figure 2 and Table 2). The pro-
portion of patients achieving an MDA response at week 24 (key 
secondary end point) was significantly greater among patients 
receiving etanercept monotherapy compared with those receiv-
ing methotrexate monotherapy (102 [35.9%] of 284 patients 
versus 65 [22.9%] of 284 patients; adjusted P = 0.005) and 
significantly greater among those receiving combination ther-
apy compared with those receiving methotrexate monotherapy 
(101 [35.7%] of 283 patients versus 65 [22.9%] of 284 patients; 
adjusted  P = 0.005) (Table 2 and Figure 2).
The proportion of patients achieving an ACR50 response 
at week 24 was greater for the etanercept monotherapy group 
compared with the methotrexate monotherapy group (114 
[44.4%] of 257 patients versus 77 [30.6%] of 252 patients; 
unadjusted P = 0.006) and for the combination therapy group 
compared with the methotrexate monotherapy group (117 
[45.7%] of 256 patients versus 77 [30.6%] of 252 patients; 
unadjusted  P < 0.001) (Table  2 and Figure  2). Similarly, the 
proportion of patients achieving an ACR70 response at week 
24 was greater with etanercept monotherapy compared with 
methotrexate monotherapy (75 [29.2%] of 257 patients ver-
sus 35 [13.8%] of 253 patients; unadjusted P  <  0.001) and 
greater with combination therapy compared with methotrexate 
monotherapy (71 [27.7%] of 256 patients versus 35 [13.8%] of 
253; unadjusted P < 0.001) (Table 2 and Figure 2). Although 
not formally tested for comparison, the ACR improvement 
responses and MDA response were similar between the com-
bination therapy and etanercept monotherapy arms (Table 2). 
The proportions of patients achieving ACR20, ACR50, ACR70, 
and MDA responses at week 48 were consistent with those 
seen at week 24 (results for all 48- week outcomes are shown 
in Supplementary Table 3, available on the Arthritis & Rheuma-
tology web site at http://onlinelibrary.wiley.com/doi/10.1002/
art.40851/abstract).
The mean change in SHS score from baseline at week 48 
indicated that there was less radiographic progression in patients 
who received etanercept monotherapy compared with those 
who received methotrexate monotherapy (mean ± SEM change 
−0.04 ± 0.04 versus 0.08 ± 0.03; unadjusted P = 0.014), and 
less ra diographic progression in those who received combina-
tion therapy compared with those who received methotrexate 
Figure 2. Percentage of patients achieving treatment responses 
based on the American College of Rheumatology 20% improvement 
criteria (ACR20) (A), ACR50 (B), and ACR70 (C) and the Minimal 
Disease Activity (MDA) response (D) over time (from baseline to week 
48). Data are reported as observed (patients who received rescue 
therapy remained in their randomized treatment arm). * = unadjusted 
P < 0.05; † = unadjusted P < 0.01; ‡ = unadjusted P ≤ 0.001, versus 
methotrexate (MTX) monotherapy. ETN = etanercept.
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Table 2. Primary, key secondary, and select other end points at 24 weeks*
Methotrexate  
monotherapy 
(n = 284)
Etanercept 
monotherapy 
(n = 284)
P, etanercept 
monotherapy vs. 
methotrexate 
monotherapy
Combination 
therapy 
(n = 283)
P, combination 
therapy vs. 
methotrexate 
monotherapy
ACR improvement response, 
no./total (%)
ACR20 144/284 (50.7) 173/284 (60.9) 0.029† 184/283 (65.0) 0.005†
ACR50 77/252 (30.6) 114/257 (44.4) 0.006 117/256 (45.7) <0.001
ACR70 35/253 (13.8) 75/257 (29.2) <0.001 71/256 (27.7) <0.001
MDA response, no./total (%) 65/284 (22.9) 102/284 (35.9) 0.005† 101/283 (35.7) 0.005†
VLDA response, no./total (%) 12/252 (4.8) 39/257 (15.2) <0.001 37/258 (14.3) <0.001
PASDAS, mean ± SEM change 
from baseline (no. assessed)
−1.98 ± 0.10 (246) −2.64 ± 0.10 
(250)
<0.001 −2.63 ± 0.11 
(255)
<0.001
DAPSA, mean ± SEM change 
from baseline (no. assessed)
−22.6 ± 1.4 (251) −25.0 ± 1.3 
(253)
0.24 −24.9 ± 1.4 
(256)
0.23
LDI
Mean ± SEM change from 
baseline (no. assessed)
−128.8 ± 26.8 (89) −119.1 ± 20.7 
(89)
0.85 −110.2 ± 22.7 
(87)
0.68
Resolution, no./total (%) 58/89 (65.2) 68/89 (76.4) 0.12 69/87 (79.3) 0.057
SPARCC Enthesitis Index
Mean ± SEM change from 
baseline (no. assessed)
−3.1 ± 0.3 (167) −3.0 ± 0.3 (173) 0.93 −2.9 ± 0.3 (179) 0.70
Resolution, no./total (%) 72/167 (43.1) 91/173 (52.6) 0.11 85/179 (47.5) 0.55
Psoriasis- affected BSA,
mean ± SEM % improvement
from baseline (no. assessed) 
Patients with ≥3% BSA 
affected at baseline
66.1 ± 2.8 (179) 69.8 ± 2.7 (166) 0.49 75.5 ± 3.7 (163) 0.031
Patients with ≥10% BSA 
affected at baseline
65.7 ± 3.7 (92) 74.2 ± 3.3 (91) 0.12 81.6 ± 2.6 (86) <0.001
sPGA, status clear or almost
clear, no./total (%)‡
Patients with ≥3% BSA  
affected at baseline 
118/178 (66.3) 120/166 (72.3) 0.40 125/161 (77.6) 0.019
Patients with ≥10% BSA 
affected at baseline
54/91 (59.3) 72/91 (79.1) 0.012 67/85 (78.8) 0.004
mNAPSI 
Mean ± SEM change from 
baseline (no. assessed)
−1.1 ± 0.2 (121) −1.5 ± 0.2 (115) 0.10 −1.7 ± 0.2 (123) 0.020
Patients achieving a score of 
1, no./total (%)
47/121 (38.8) 50/115 (43.5) 0.44 60/123 (48.8) 0.14
HAQ DI, mean ± SEM change 
from baseline (no. assessed)
−0.41 ± 0.04 (252) −0.44 ± 0.04 
(258)
0.67 −0.47 ± 0.04 
(257)
0.34
SF- 36, mean ± SEM change
from baseline (no. assessed)
Total score 9.2 ± 0.8 (253) 10.6 ± 0.8 (256) 0.31 11.3 ± 0.9 (257) 0.11
PCS score 6.0 ± 0.6 (253) 7.8 (0.6) (256) 0.033 8.0 ± 0.6 (257) 0.015
MCS score 3.3 ± 0.6 (253) 2.8 (0.6) (256) 0.56 3.3 ± 0.6 (257) 0.97
(continued)
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 monotherapy (mean ± SEM change −0.01 ± 0.03 versus 0.08 ± 
0.03; unadjusted P = 0.041) (Table 2). The cumulative probabil-
ity plot of the change in SHS from baseline at week 48 showed 
a lower likelihood of radiographic progression in the etanercept- 
containing treatment arms compared with the methotrexate mon-
otherapy arm (Figure 3).
Consistent results were seen with rates of radiographic 
progression at week 48 (see Supplementary Figure 2, availa-
ble on the Arthritis & Rheumatology web site at http://online 
library.wiley.com/doi/10.1002/art.40851/abstract). Moreover, the 
rates of radiographic nonprogression were similar between each 
etanercept- containing treatment arm.
The VLDA response at week 24 was greater in patients 
receiving etanercept monotherapy compared with those receiv-
ing methotrexate monotherapy (39 [15.2%] of 257 patients 
versus 12 [4.8%] of 252 patients; unadjusted P < 0.001), and 
in those receiving combination therapy compared with those 
receiving methotrexate monotherapy (37 [14.3%] of 258 
patients versus 12 [4.8%] of 252 patients; unadjusted P < 0.001) 
(Table 2).
Analysis of changes in disease activity levels showed that the 
mean improvement in the PASDAS score from baseline at week 
24 was greater in the etanercept- containing treatment arms com-
pared with the methotrexate monotherapy arm (Table 2). Further-
more, the mean improvement in the DAPSA score from baseline 
at week 24 was numerically greater in the etanercept- containing 
treatment arms compared with the methotrexate monotherapy 
arm, but the differences were modest (Table 2). The results for 
these end points were similar for both the etanercept monother-
apy and combination therapy arms (Table 2).
Although numerical trends were observed, no meaningful dif-
ferences were seen in the percentage of patients who achieved 
clear scores on the LDI or SPARCC Enthesitis Index by week 24 
between the etanercept- containing and methotrexate monother-
apy treatment arms (Table 2). Furthermore, although not formally 
tested, results for the LDI and SPARCC Enthesitis Index were sim-
ilar in both etanercept- containing treatment arms (Table 2).
Figure 3. Cumulative probability plot of the change from baseline 
in the van der Heijde modification of the total Sharp score (SHS) 
of radiographic progression at week 48 in the methotrexate 
monotherapy, etanercept monotherapy, and combination therapy 
study arms. At week 48, progression (change from baseline in 
SHS >0) was seen in 23 patients (10.6%), 12 patients (5.3%), and 
12 patients (5.3%) in the methotrexate monotherapy, etanercept 
monotherapy, and combination therapy arms, respectively.
Methotrexate  
monotherapy 
(n = 284)
Etanercept 
monotherapy 
(n = 284)
P, etanercept 
monotherapy vs. 
methotrexate 
monotherapy
Combination 
therapy 
(n = 283)
P, combination 
therapy vs. 
methotrexate 
monotherapy
SHS score
Mean ± SEM change from 
baseline at week 48 (no. 
assessed)
0.08 ± 0.03 (216) −0.04 ± 0.04 
(225)
0.014 −0.01 ± 0.03 
(226)
0.041
Nonprogression at week 48, 
no./total (%)§
193/216 (89.4) 213/225 (94.7) 0.088 214/226 (94.7) 0.033
* All end points were measured at 24 weeks, except for the van der Heijde modification of the total Sharp score (SHS) of radiographic pro-
gression, which was measured at 48 weeks. VLDA = Very Low Disease Activity; PASDAS = Psoriatic Arthritis Disease Activity Score; DAPSA = 
Disease Activity Index for Psoriatic Arthritis; LDI = Leeds Dactylitis Index; SPARCC = Spondyloarthritis Research Consortium of Canada; BSA = 
(psoriasis- affected) body surface area; mNAPSI = modified Nail Psoriasis Severity Index; HAQ DI = Health Assessment Questionnaire disabil-
ity index; SF- 36 = Short- Form 36 Health Survey; PCS = physical component summary; MCS = mental component summary. 
† P values for the American College of Rheumatology 20% improvement (ACR20) response rates at week 24 (primary end point) and Minimal 
Disease Activity (MDA) response rates at week 24 (key secondary end point) were tested in a Bonferroni- based gatekeeping procedure and 
stratified by body mass index category and prior nonbiologic disease- modifying antirheumatic drug use. All other P values were unadjusted. 
‡ A status of clear on the static Physician’s Global Assessment (sPGA) of psoriasis was defined as a score of 0, and a status of almost clear 
was defined as a score of 1. The score scale ranges from 0 (clear) to 5 (severe). 
§ Radiographic nonprogression was defined as a change in the SHS of ≤0 from baseline to week 48. 
Table 2. (Cont’d)
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In patients with ≥3% or ≥10% BSA affected by psoriasis at 
baseline, analyses at week 24 showed that there was greater 
mean percentage improvement in psoriasis- affected BSA in 
patients who received combination therapy compared with those 
who received methotrexate monotherapy. Moreover, a greater 
percentage of patients in the combination therapy group had clear 
or almost clear sPGA scores compared with those in the metho-
trexate monotherapy arm (Table 2).
The number of patients who experienced improvements in 
psoriasis- affected BSA was numerically higher in the etanercept 
monotherapy arm compared with the methotrexate monother-
apy arm. Moreover, a greater percentage of patients receiving 
etanercept monotherapy had clear or almost clear sPGA scores 
compared with patients receiving methotrexate monotherapy.
In contrast to the distributions of ACR and MDA response 
rates, more patients in the combination therapy group expe-
rienced numerically higher improvements in skin end points 
compared with patients in the etanercept monotherapy group 
(Table  2). At week 24, none of the patients achieved a clear 
mNAPSI score, but when the percentage of patients achieving 
an mNAPSI score of 1 was examined, small differences between 
the treatment arms were seen (Table 2).
In each of the 3 study arms, there were improvements 
from baseline at week 24 in the HAQ DI and SF- 36 total health 
function scores. Differences in the SF- 36 total score and SF- 36 
mental component summary score were minimal between the 
study arms, but the SF- 36 physical component summary score 
showed a greater mean change from baseline at week 24 in the 
etanercept- containing arms compared with the methotrexate 
monotherapy arm (Table 2).
Over this 48- week study, rates of adverse events, serious 
adverse events, and adverse events that led to discontinua-
tion of the investigational product were similar across the 3 
study arms (Table  3). The rates of any adverse events were 
212 (75.2%) of 282 patients receiving methotrexate monother-
apy, 191 (67.7%) of 282 patients receiving etanercept mono-
therapy, and 216 (76.1%) of 284 patients receiving combina-
tion therapy. Of note, nausea occurred more commonly in the 
methotrexate- containing arms (37 [13.1%] of 282 patients in 
the methotrexate monotherapy arm and 41 [14.4%] of 284 
patients in the combination therapy arm compared with 18 
[6.4%] of 282 patients in the etanercept monotherapy arm). 
Injection site reactions occurred more commonly in the 
etanercept- containing arms (5 [1.8%] of 282 patients in the 
etanercept monotherapy arm and 8 [2.8%] of 284 patients 
in the combination therapy arm compared with 1 [0.4%] of 
282 patients in the methotrexate monotherapy arm). No fatal 
adverse events were reported.
DISCUSSION
The SEAM- PsA trial contributes to our understanding of 
how best to treat patients early in the course of PsA who are 
naive to treatment with methotrexate and to biologic DMARDs. 
The results of this study demonstrate that etanercept as 
 monotherapy and in combination with methotrexate is  superior 
Table 3. Summary of safety results at 48 weeks*
Methotrexate monotherapy 
(n = 282)
Etanercept monotherapy 
(n = 282)
Combination therapy 
(n = 284)
Any adverse event 212 (75.2) 191 (67.7) 216 (76.1)
Serious adverse event† 16 (5.7) 19 (6.7) 17 (6.0)
Adverse events leading to discon-
tinuation of investigational 
product
19 (6.7) 16 (5.7) 20 (7.0)
Treatment- related adverse events 64 (22.7) 71 (25.2) 79 (27.8)
Fatal adverse events 0 (0.0) 0 (0.0) 0 (0.0)
Adverse events occurring in ≥5%
of patients
Nausea 37 (13.1) 18 (6.4) 41 (14.4)
Nasopharyngitis 22 (7.8) 21 (7.4) 27 (9.5)
Upper respiratory tract infection 21 (7.4) 18 (6.4) 23 (8.1)
Diarrhea 17 (6.0) 13 (4.6) 14 (4.9)
Headache 15 (5.3) 12 (4.3) 17 (6.0)
Bronchitis 9 (3.2) 14 (5.0) 19 (6.7)
Vomiting 15 (5.3) 7 (2.5) 10 (3.5)
* Adverse events were categorized using the Medical Dictionary for Regulatory Activities, version 21. Values are the number (%) of patients. 
† The most common serious adverse events were of the system organ class infections and infestations, which occurred in 1.1% of patients in 
the methotrexate monotherapy arm, 2.8% of patients in the etanercept monotherapy arm, and 2.5% of patients in the combination therapy 
arm. 
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to methotrexate monotherapy when assessed according 
to the proportion of patients experiencing ACR20 and MDA 
responses (the primary and key secondary end points of the 
trial, respectively). The ACR50 and ACR70 responses and the 
PsA- specific composite measures (VLDA and PASDAS) also 
showed greater efficacy with etanercept monotherapy and 
combination therapy compared with methotrexate monother-
apy. The etanercept- containing treatment arms also showed 
less radiographic progression compared with the methotrex-
ate monotherapy arm. In general, the addition of methotrex-
ate to etanercept did not contribute meaningfully to the over-
all efficacy of etanercept monotherapy, except in the case of 
some of the skin end points, for which combination therapy 
appeared to have increased efficacy.
The results of this study represent a detailed characteriza-
tion of the efficacy of methotrexate monotherapy relative to a TNF 
inhibitor across a broad spectrum of PsA clinical manifestations 
in patients with early PsA. To overcome a key criticism of the 
MIPA trial (21), in which the target methotrexate dosage was 15 
mg/week, the SEAM- PsA trial stipulated a target dosage of 20 
mg/week and achieved mean dosages of methotrexate in the 2 
methotrexate- containing arms of >18.8 mg/week from weeks 4 
to 24.
As a comparator study, the SEAM- PsA trial had no separate 
placebo arm, so the interpretation of the efficacy of methotrexate 
across the various clinical end points needs to be considered rel-
ative to etanercept. Nevertheless, methotrexate showed generally 
good efficacy across multiple domains, which is consistent with 
the Tight Control of PsA (TICOPA) study, which examined meth-
otrexate monotherapy in PsA (48). Although numerical trends 
were observed, no substantial differences were noted between 
the etanercept and methotrexate monotherapy arms in terms of 
enthesitis and dactylitis scores and change in psoriasis- affected 
BSA from baseline (when examined among patients with ≥3% 
BSA involved with psoriasis at baseline). However, patients with 
≥10% BSA involved with psoriasis at baseline were more likely to 
achieve clear or almost clear status by week 24 in the etanercept 
monotherapy or combination therapy groups compared with the 
methotrexate monotherapy group.
In addition, no clear differences in the HAQ DI or SF- 36 
scores were noted between the 3 study arms, except for the 
SF- 36 physical component summary score, which showed a 
greater mean change from baseline at week 24 in the etanercept- 
containing treatment arms compared with the methotrexate 
monotherapy arm. Overall, these results support the use of 
etanercept as monotherapy without the need for concomitant 
methotrexate, and also provide information about methotrexate 
when used as monotherapy.
Some limitations of this study should be noted. The study 
did not consider axial disease in the eligibility criteria. In addition, 
the study included patients with mostly polyarticular disease (with 
mean swollen joint counts and tender joint counts of ~12 and 
~30, respectively), which limits the generalizability of the results to 
those patients with oligoarticular disease and/or axial involvement. 
While the study was designed to characterize the relative efficacy 
of etanercept and methotrexate, there is significant interest in the 
study data with regard to efficacy of methotrexate monotherapy. 
However, the absence of a placebo group in this study limits the 
ability to draw firm conclusions about the efficacy of methotrexate 
monotherapy.
Disease modification is an important clinical consideration 
in the treatment of PsA. Investigators have demonstrated the 
ability of etanercept to inhibit radiographic progression in PsA 
(49), but the effect of methotrexate on radiographic progression 
has not been studied in a placebo- controlled trial. Since the 
SEAM- PsA study did not enrich for patients with radiographic 
evidence of PsA, only a small subset of patients, as expected, 
showed radiographic changes over a 48- week period. Moreover, 
any differences between the methotrexate monotherapy arm 
and the etanercept monotherapy arm at week 48 would have 
been blunted by the 24.3% of patients in the methotrexate 
monotherapy arm who received rescue combination therapy 
starting at or after week 24. These results demonstrate that 
etanercept is associated with a lower degree of radiographic 
progression compared with methotrexate, and that combining 
methotrexate and etanercept may not have any discernible 
effect on radiographic progression as compared with etanercept 
monotherapy. Although the magnitude of the effects was small, 
the differences were clear for this clinically important end point. 
The lack of a placebo arm limits the ability to interpret the effect 
of methotrexate alone on radiographic progression, and these 
results (as for the other end points) should be interpreted relative 
to those in the other treatment arms.
MDA response was included as the key secondary end point 
in this trial to highlight the importance of more comprehensively 
capturing the unique clinical manifestations of PsA when com-
pared with the “joint- centric” ACR response measures. The MDA 
criteria evaluate PsA disease activity using measures of joint and 
entheseal inflammation, skin disease, patient- reported outcomes, 
and functional disability (24,35,50–52). The MDA response rates in 
this study were consistent with the ACR20, ACR50, and ACR70 
response rates in terms of showing greater responses in the 
etanercept- containing treatment arms compared with the meth-
otrexate monotherapy arm; no additional efficacy was observed 
with combination therapy compared with etanercept monotherapy.
In addition to the MDA response, other PsA- specific out-
come measures were included in this study in support of the over-
all findings. The VLDA response has recently become a clinically 
relevant benchmark that utilizes the same components as the 
MDA but with response defined as meeting all 7 MDA criteria. 
PASDAS and DAPSA are additional measures (with PASDAS cov-
ering a broader spectrum of PsA manifestations) that assess a 
binary outcome in PsA and also provide a continuous measure of 
disease activity. The PASDAS scores were consistent with those 
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seen for the ACR and MDA responses, but the DAPSA scores 
showed similar outcomes across all 3 study arms. Consistent with 
the other end points, methotrexate did not contribute additional 
efficacy to etanercept alone.
Many patients in this trial had a moderate- to- severe level 
of psoriasis, as assessed by the percentage of psoriasis- 
affected BSA. Results with regard to the dermatologic end 
points showed that etanercept and methotrexate had good 
efficacy, with a suggestion that the combination treatment arm 
had slightly greater efficacy than either of the monotherapy 
treatment arms in terms of improvement in the percentage of 
psoriasis- affected BSA, sPGA scores, and mNAPSI scores. 
The fact that etanercept was more effective in combination 
with methotrexate for the skin- related end points is consistent 
with results reported in a prior study (53); it should also be 
noted that etanercept monotherapy was administered at 50 
mg once per week in this study, but is indicated for use at 50 
mg twice per week to treat psoriasis in adults (33).
The observed varied impact of methotrexate, both alone 
and as an addition to etanercept, across these individual man-
ifestations provides insights about the potentially context- 
dependent and heterogeneous drivers of PsA pathology. 
Taken as a whole, the SEAM- PsA trial results are remarkably 
different from those of the TEMPO trial in rheumatoid arthritis 
(28), in which the combination of etanercept and methotrex-
ate was more effective than etanercept monotherapy, which 
underscores the pathophysiologic differences between rheu-
matoid arthritis and PsA (54).
Differences among TNF inhibitors have been noted in 
terms of their effects on long- term survival in patients in clinical 
 registries, when the impact of using a TNF inhibitor as mono-
therapy has been compared with a TNF inhibitor in combination 
with methotrexate (29,55). These differences should be taken 
into account when considering the use of TNF inhibitors as 
monotherapy or in combination with methotrexate. Because of 
patients’ and physicians’ concerns with regard to the tolerability 
and safety of methotrexate, a clear understanding of its clini-
cal benefits, alone or in combination with TNF inhibitors, is an 
important aspect of clinical decision- making. Thus, the charac-
terization in this trial of the safety and tolerability of both metho-
trexate monotherapy and biologic monotherapy provides impor-
tant information when considering the safety profile (including 
immunogenicity) associated with PsA treatment approaches.
Overall, these results provide information that is of practical 
value for clinical practice, in terms of both demonstrating the rel-
ative efficacy of methotrexate and etanercept and characterizing 
the impact of combining methotrexate and etanercept across a 
broad range of PsA clinical manifestations.
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Clinical Images: Hypophysis involvement in granulomatosis with polyangiitis
The patient, a previously healthy 25- year- old woman, presented with a 3- month history of new- onset headaches, polyuria, and polydipsia. 
There was no infection, trauma, or drug intake reported prior to symptoms. Physical examination findings were unremarkable; results of lab-
oratory testing were consistent with increased levels of markers of inflammation along with hypernatremia, high serum osmolality, and low 
urine osmolality. Water deprivation test findings were suggestive of central diabetes insipidus. Magnetic resonance imaging (MRI) revealed a 
large pituitary mass measuring 17 × 17 × 12 mm (A) (arrow and arrowhead) compressing the intracranial portions of the optic nerves and 
chiasm. Surgical intervention, including pituitary biopsy and debulking, was performed. Histopathologic studies showed necrotic granuloma 
characterized by epithelioid histiocytes, multinucleated giant cells, neutrophils, eosinophils, and plasma cells (B) (arrows). Findings on chest 
computed tomography and serum angiotensin- converting enzyme levels were normal. Tuberculin skin test results were negative. Further 
laboratory data revealed proteinase 3 antineutrophil cytoplasmic antibodies. The patient was diagnosed as having granulomatosis with 
polyangiitis (GPA). There was no evidence of other organ system involvement. She was started on oral prednisone and pulse cyclophos-
phamide (CYC). At 8 months, her clinical condition was stable without residual or recurrent disease seen on MRI. Involvement of the pituitary 
gland in GPA is  uncommon, with an estimated prevalence of nearly 1% (1,2). Generally, patients with pituitary involvement are younger, 
and symptoms of pituitary disease precede other systemic features (3). Immunosuppressive therapy is needed to control disease activity in 
GPA, and glucocorticoids along with rituximab, CYC, or methotrexate have been used to treat pituitary involvement (3). In our patient, early 
treatment with high- dose steroids and pulse CYC resulted in a good outcome after 8 months, although permanent desmopressin treatment 
was required as a consequence of surgery.
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